Pharmacokinetics of 111In-DOTA-non-targeted mIFNα2 and 111In-DOTA- targeted mIFNα2 in mouse kidney after a single 20 μg/kg intravenous dose.
收藏Figshare2015-12-03 更新2026-04-29 收录
下载链接：
https://figshare.com/articles/dataset/_Pharmacokinetics_of_111_In_DOTA_non_targeted_mIFN_945_2_and_111_In_DOTA_targeted_mIFN_945_2_in_mouse_kidney_after_a_single_20_956_g_kg_intravenous_dose_/1310948
下载链接
链接失效反馈官方服务：
资源简介：
In kidney, 111In-DOTA-targeted mIFNα2 had a terminal half-life of 75.4 hours, Cmax of 327 ng/g, Tmax of 2 hours, an AUC(0-∞) of 34,795 hr*ng/g, an AUC(0–12) of 3,551 hr*ng/mL and an AUC(0–24) of 6,899 hr*ng/mL. 111In-DOTA-non-targeted mIFNα2 had a terminal half-life of 84.1 hours, Cmax of 736 ng/g, Tmax of 12 hours, an AUC(0-∞), an AUC(0–12) of 7,776 hr*ng/mL and an AUC(0–24) of 15,874 hr*ng/mL of 91,128 hr*ng/g.Pharmacokinetics of 111In-DOTA-non-targeted mIFNα2 and 111In-DOTA- targeted mIFNα2 in mouse kidney after a single 20 μg/kg intravenous dose.
创建时间：
2015-12-03
